Stock Analysis, Dividends, Split History

TTNP / Titan Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.89
Volume58,100.00
Market Cap ($M)19.72
Enterprise Value ($M)19.67
Book Value ($M)-0.85
Book Value / Share-0.04
Price / Book-23.31
NCAV ($M)-1.39
NCAV / Share-0.07
Price / NCAV-14.22
Share Statistics
Common Stock Shares Outstanding 21,203,744
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 21,203,744
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.92
Return on Assets (ROA)-0.77
Return on Equity (ROE)-1.08
Balance Sheet (mrq) ($M)
Assets5.29
Liabilities6.14
Quick Ration/a
Current Ratio1.75
Income Statement (mra) ($M)
Revenues215,000.00
Revenue From Grants0.00
Royalty Revenue0.00
Licenses Revenue215,000.00
Operating Income-14.50
Net Income-14.31
Earnings Per Share Basic-0.67
Earnings Per Share Diluted-0.70
Cash Flow Statement (mra) ($M)
Cash From Operations-13.04
Cash from Investing-0.17
Cash from Financing-0.17
Identifiers and Descriptors
CUSIP888314309
Central Index Key (CIK)910267
Related CUSIPS
888314959 888314909 888314101

Split History

Stock splits are used by Titan Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Your Daily Pharma Scoop: Eagle Gets New Patent, Ocular Refiles NDA, Antibe's Phase 2b Data Announced

2018-07-05 seekingalpha
Discussion: Eagle Pharmaceuticals Inc. (EGRX) is a specialty pharmaceutical company focused on developing and commercializing injectable products for oncology and critical care segments. The lead candidate of the company, Bendeka (bendamustine hydrochloride), received the U.S. Patent No. 10,010,533. The patent covers the drug’s use in blood cancer. The IP of the company now goes up to 15 patents. Teva Pharma (NYSE:TEVA) owns exclusive U. (63-1)

Titan Pharma Receives Go-Ahead with Parkinson’s Trial, But Chooses to Hold Off

2018-07-03 biospace
An independent Data Safety Monitoring Board (DSMB) recommended that Titan Pharmaceuticals’ Phase I/II trial of its ropinirole implant for Parkinson’s disease continue with a second cohort of patients. However, the company has decided to temporarily halt the study and focus on another asset. (19-0)

Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q1 2018 Results - Earnings Call Transcript

2018-05-17 seekingalpha
Thank you for holding and welcome to the Titan Pharmaceuticals First Quarter 2018 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being taped at the company’s request and will be archived on the company’s website starting later today. At this time, I would like to turn the call over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals. Please go ahead. (16-2)

Horizon Technology Finance's (HRZN) CEO, Robert Pomeroy on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good morning and welcome to Horizon Technology Finance’s first quarter 2017 conference call. Today’s call is being recorded. All lines have been placed on mute. We will conduct a question and answer session after the opening remarks. Instructions will follow at that time. (18-1)

3 Stocks to Watch on Tuesday: Atlas Financial Holdings Inc (AFH), Eastside Distilling Inc (EAST) and Titan Pharmaceuticals, Inc. (TTNP) | InvestorPlace

2018-04-03 investorplace
U.S. stocks plummeted Monday as the tech industry was hit hard and Amazon.com, Inc. (NASDAQ:AMZN) experienced a selloff, falling 5%. The S&P 500 Index fell 2.2%, the Dow Jones Industrial Average slid 1.9% and the Nasdaq Composite fell 2.7%. (113-1)

CUSIP: 888314309